TrialSignal
Clinical trial intelligence report
Phase 1/2 Multicenter, Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-3001 in Participants with Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT06622668
Status
WITHDRAWN
Phase
Phase 1/2
Sponsor
Intellia Therapeutics
Executive brief
Investment-Ready Snapshot
NTLA-3001, developed by Intellia Therapeutics, targets a niche yet significant patient population suffering from AATD-associated lung disease. The market for AATD therapies is currently underserved, with limited treatment options available. The withdrawal of this trial indicates a strategic shift by Intellia towards prioritizing other programs, which may reflect resource allocation challenges or a reassessment of the commercial viability of NTLA-3001. Competitively, the gene editing landscape is rapidly evolving, and Intellia's focus on AAV and CRISPR technologies positions it well, but the withdrawal may raise concerns regarding the asset's future development and market entry.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT06622668
Indication
Lung Disease
Modality
protein therapy
Target
Alpha-1 Antitrypsin Deficiency (AATD) - associated lung disease, utilizing AAV and CRISPR/Cas9 gene editing technology.
Intervention
Biological NTLA-3001
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.